Monmouth Junction, NJ, USA—April 27, 2009— MicroDose Technologies, a leader in next generation drug delivery technologies, is now MicroDose Therapeutx (MDT). Founded in 1998 with the introduction of its revolutionary electronic dry powder inhaler among other technologies, privately held MicroDose Therapeutx focuses on the creation of products utilizing its proprietary drug delivery technologies.
The MDT name change reflects the expansion of its business, its capabilities and its products. The company plans to expand its portfolio from primarily third party products incorporating its technologies to one that includes internally developed specialty pharmaceutical products. Utilizing its game changing drug delivery technologies, MicroDose Therapeutx plans to create easy to use therapies with improved performance, safety and efficacy. In addition to its new name, MDT has launched a new web site, www.mdtx.com.
MDT’s focus in pulmonary delivery is on inhalation therapies for respiratory diseases like asthma and COPD, and supportive care for respiratory illnesses, such as pulmonary infections. Other priority areas include treatments for pain, diabetes and pulmonary hypertension, where pulmonary delivery can enhance efficacy. For oral dosage products utilizing our PolyCap® system, we will focus on products that enhance treatment effectiveness in patients suffering from major diseases like diabetes, hypertension, and hyperlipidemia.
Describing the new vision for the company, Anand Gumaste, President and Chief Executive Officer, states, “The name change reflects our decision to expand the company’s business model from a strictly technology out-licensing model to one where the company would also carry certain pharmaceutical products through proof-of-concept before out-licensing or seeking partners for further development. This expansion of our business strategy will give us a greater degree of control over the company’s growth.”
About MicroDose Therapeutx
MicroDose Therapeutx (MDT), formerly MicroDose Technologies, is dedicated to improving the quality of life for people suffering from serious diseases by creating improved pharmaceutical products. The company is a leader in the application of proprietary drug delivery technologies; developing advanced pulmonary, combination oral dosage; and other technologies and products for the pharmaceutical and biotechnology industries.
MicroDose’s partners and programs include: multi-product licensing and development agreements with Novartis and Merck & Co., Inc., the joint development of an inhaled insulin product, and an inhaler for the delivery of a nerve agent antidote for the US Department of Defense.
Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or firstname.lastname@example.org